Intervention
Participants who met the inclusion criteria were randomly divided into two groups at a 1:1 ratio. Patients in the test group (n = 67) were randomly treated with beinaglutide and metformin, whereas patients in the control group (n = 67) were randomly treated with aspart 30 and metformin, with a follow-up period of 6 months. The recommended dosage of beinaglutide is 0.1mg three times daily (tid) by subcutaneous injection in the upper arm, thigh, or abdomen. The dosage may be increased to 0.2 mg tid if the glycemic response is inadequate (